s daily healthcare newsletter
, your daily dose of pharma, biotech, and healthcare news.
Subscribe here to get this newsletter in your inbox every weekday.
Today in healthcare news: Walmart’s quietly building a startup that wants to use data to help customers make healthier choices, a senior living chain is requiring employees to get shots, and Verve’s building a gene-editing treatment for heart disease.
- Walmart is building a new health venture through its incubation arm Store No.8, Business Insider has learned.
- The venture, which doesn’t have a name yet, will aim to help shoppers make healthier choices based on their own shopping data.
- It builds on Walmart’s healthcare business, which includes clinics and pharmacies.
Paul Bersebach/MediaNews Group/Orange County Register via Getty ImagesA CVS pharmacist gives the Pfizer/BioNTech COVID-19 vaccine to a resident at the Emerald Court senior living community in Anaheim, California.
A major chain of senior living facilities will require more than 10,000 workers to get COVID-19 shots
- Atria Senior Living, a large operator of independent living, assisted living, and other senior living facilities, is requiring more than 10,000 US employees to get the COVID-19 vaccine.
- Atria CEO John Moore told Business Insider that requiring the vaccine is “the responsible thing to do” to stop the spread of the coronavirus among staff and residents.
- Several other long-term care companies told Business Insider they are not mandating the coronavirus vaccine.
- Employers can require staff to give COVID-19 shots without running afoul of the law, according to federal guidance, and more employers are expected to follow in Atria’s footsteps.
Verve is gearing up to test a gene-editing treatment that could cure heart disease. The CEO shares his 3-step vision for the one-and-done heart treatment.
- A buzzy Cambridge, Massachusetts biotech is advancing its research on a gene-editing treatment for heart disease.
- Verve Therapeutics CEO Sekar Kathiresan outlined the company’s three-stage strategy to ultimately cure heart disease.
- Verve’s first treatment candidate uses a next-generation gene-editing tool called base-editing to change a single letter in a person’s genetic code. That edit will lower levels of bad cholesterol, the company hopes.
More stories we’re reading:
- One of digital health’s only dedicated early-stage venture firms just raised $US200 million for its second fund. Here’s how founder Lynne Chou O’Keefe plans to spend it. (Business Insider)
- Uber and Lyft are pushing for a role in vaccine rollout(The Wall Street Journal)
- Answers to your 24 most burning questions about the coronavirus vaccine, from side effects and costs to when you’ll be able to get one (Business Insider)
- One of Intarcia’s key investors wrote down its stake former unicorn Intarcia (Stat News)
Business Insider Emails & Alerts
Site highlights each day to your inbox.